|
An innovative, internet-based assessment of financial toxicity (FT), psychological distress, and quality of life (QOL) in ovarian cancer survivors (OCS). |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Research Funding - Leap Therapeutics (Inst) |
|
|
Stock and Other Ownership Interests - FACIT.org |
Consulting or Advisory Role - Abbvie; Actinium Pharmaceuticals; Asahi Kasei; Astellas Pharma; Bristol-Myers Squibb; Corcept Therapeutics; GlaxoSmithKline; IDDI; Ipsen; Ipsen; Novartis; Pfizer; PledPharma |
Research Funding - Abbvie (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Genentech (Inst); GlaxoSmithKline (Inst); Ipsen (Inst); Novartis (Inst); Pfizer (Inst); PledPharma (Inst); Regeneron (Inst) |
Travel, Accommodations, Expenses - Ipsen; PledPharma |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - Daiichi Sankyo |